Cytokine-Driven Immunopathogenesis of Psoriasis: Clinical Therapeutic Targets and Future Immunologic Directions

Abstract

Background: Psoriasis is a chronic inflammatory skin disorder affecting ~2% of the global population, characterized by erythematous, scaly plaques. It involves a complex interplay of immune dysregulation and genetic susceptibility.

Pathogenesis: The disease is driven by persistent activation of immune cells and overproduction of pro-inflammatory cytokines. Genome-wide association studies have identified polymorphisms in genes encoding cytokines, their receptors, and signalling molecules, highlighting their central role. Elevated serum cytokine levels and their overexpression in psoriatic lesions correlate with disease severity.

Immunological Insights: Initially considered a type-1 immune-mediated disorder due to the involvement of cytokines such as interferon-γ, interleukin-2 (IL-2), and interleukin-12 (IL-12), psoriasis understanding has evolved significantly. The discovery of T helper 17 cells (Th17 cells) and their associated cytokines has redefined its immunopathology and provided new therapeutic targets.

Contributing Factors: Psoriasis develops in genetically predisposed individuals through interactions between environmental triggers and immune responses.

Therapeutic Advances: Targeted cytokine-based therapies, including biologics, have improved disease management by specifically modulating key inflammatory pathways.

Conclusion: Cytokine dysregulation is central to psoriasis pathogenesis, and continued exploration of cytokine networks offers promising avenues for more effective and personalized treatments.